Veru Inc (VERU) Stock Price, Quote & News

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to preven...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 509 6897

Website: verupharma.com

Address:

2916 North Miami Avenue, Suite 1000, Miami, United States

mrkymrk Jun. 20 at 6:58 PM

$VERU no volume whatsoever. Everyone on standby for news.

0 · Reply

PennyConnection1 Jun. 20 at 5:16 PM

$VERU

1 · Reply

Woundntyouliketoknow Jun. 20 at 3:44 PM

$VERU Another Scholar Rock article with a small mention of VERU: https://clival.com/news/scholar-rock-drug-preserves-muscle-in-obesity-trial

0 · Reply

mrkymrk Jun. 20 at 12:46 PM

$VERU $LLY Lilly did not PR bimagrmab data before Sunday conference and Monday poster presentation. To me this means data is ok but nothing to move the needle. Also telling that LLY continues to invest and acquire other potential muscle preserving assets. I expect big things for VERU next week. Let’s see!

0 · Reply

Zafather Jun. 20 at 12:34 PM

$VERU Reminder $JAZZ sells legalized GHB we simply want to sell legalized SARMs and get old ladies hot and juiced and old dudes beefed up like those 'Whats your age' ads. Others sell legalized ketamine, e, fenty, etc - don't tell me this isn't 'safe enough'

0 · Reply

mrkymrk Jun. 20 at 11:25 AM

$VERU Emphasis on the +

0 · Reply

Zafather Jun. 19 at 8:49 PM

$VERU Let's get juiced! 0.72+

0 · Reply

NolAsrtormZ Jun. 19 at 6:16 PM

$VERU Ok, looks like we have 2 weeks b4 Trump decides if we enter the war... Hopefully data soon

0 · Reply

AIIAAIIA_88 Jun. 19 at 2:22 PM

$VERU Short sellers are confident about VERU short positions because SARMs are still banned by FDA. But if/when FDA differentiates ENOBOSARM from other SARMs (probable) or lifts the ban on SARMs altogether (possible although unlikely), then the stock will really rocket up. JMO

1 · Reply

Woundntyouliketoknow Jun. 19 at 1:41 PM

$VERU I am still really excited today due to what Scholar Rock had for results around Apitegromab with a GLP-1. It just goes to showcase how good Veru results are in my opinion. Next up will be Lilly. Will Lilly show good results? 1) Lilly did not put out any of their results in a press release 2) Will Lilly show similar results that ScholarRock and Regeneron had (both are Anti-myostatin) 3) It looks like Lilly did not do any type of physical function test from clinicaltrials 4) Why is Lilly dropping over 600 Million on AI to develop a muscle drug if Bimagrumab works so well 5) Lilly is a IV vs Enobosarm which is a pill

1 · Reply

Veru to Participate in the Virtual BTIG Obesity Health Forum

May 28, 2025, 12:11 PM EDT - 23 days ago

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

May 28, 2025, 6:30 AM EDT - 23 days ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 26, 2025, 9:36 PM EDT - 24 days ago

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 8, 2025, 12:42 PM EDT - 6 weeks ago

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025, 9:30 AM EDT - 6 weeks ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:25 AM EDT - 6 weeks ago

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 6:30 AM EDT - 6 weeks ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 1, 2025, 8:30 AM EDT - 7 weeks ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Apr 16, 2025, 8:30 AM EDT - 2 months ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Mar 31, 2025, 8:30 AM EDT - 2 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Feb 19, 2025, 10:41 AM EST - 4 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 13, 2025, 2:35 PM EST - 4 months ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 6:30 AM EST - 4 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Jan 27, 2025, 10:34 AM EST - 5 months ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 6:30 AM EST - 5 months ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Dec 31, 2024, 8:30 AM EST - 6 months ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Nov 26, 2024, 8:30 AM EST - 7 months ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 5, 2024, 8:30 AM EST - 8 months ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Oct 21, 2024, 8:30 AM EDT - 8 months ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 16, 2024, 8:30 AM EDT - 8 months ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Sep 11, 2024, 8:30 AM EDT - 10 months ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Aug 10, 2024, 8:39 AM EDT - 11 months ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 11 months ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 1, 2024, 8:30 AM EDT - 11 months ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Jul 29, 2024, 8:30 AM EDT - 11 months ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 17, 2024, 4:45 PM EDT - 1 year ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Steven B. Heymsfield M.D.

May 14, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the GLP-1 Based Therapeutics Summit

May 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Veru Reschedules Annual Meeting of Shareholders

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Feb 27, 2024, 7:15 PM EST - 1 year ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 20, 2024, 8:30 AM EST - 1 year ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 8, 2024, 1:36 PM EST - 1 year ago

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

Feb 8, 2024, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Feb 6, 2024, 8:30 AM EST - 1 year ago

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Jan 31, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 8:30 AM EST - 1 year ago

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Jan 8, 2024, 8:30 AM EST - 1 year ago

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

Dec 19, 2023, 8:30 AM EST - 1 year ago

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

mrkymrk Jun. 20 at 6:58 PM

$VERU no volume whatsoever. Everyone on standby for news.

0 · Reply

PennyConnection1 Jun. 20 at 5:16 PM

$VERU

1 · Reply

Woundntyouliketoknow Jun. 20 at 3:44 PM

$VERU Another Scholar Rock article with a small mention of VERU: https://clival.com/news/scholar-rock-drug-preserves-muscle-in-obesity-trial

0 · Reply

mrkymrk Jun. 20 at 12:46 PM

0 · Reply

Zafather Jun. 20 at 12:34 PM

0 · Reply

mrkymrk Jun. 20 at 11:25 AM

$VERU Emphasis on the +

0 · Reply

Zafather Jun. 19 at 8:49 PM

$VERU Let's get juiced! 0.72+

0 · Reply

NolAsrtormZ Jun. 19 at 6:16 PM

$VERU Ok, looks like we have 2 weeks b4 Trump decides if we enter the war... Hopefully data soon

0 · Reply

AIIAAIIA_88 Jun. 19 at 2:22 PM

1 · Reply

Woundntyouliketoknow Jun. 19 at 1:41 PM

1 · Reply

Woundntyouliketoknow Jun. 19 at 1:31 PM

$VERU Listening to the ScholarRock investor conference from yesterday. The results were so good for their GLP-1 study that the first thing they discuss on the conference call was not the GLP-1 study but the SMA study. They even said that their corporate focus was rare diseases. During the call ScholarRock kept saying how great their results were vs GLP-1. Although it sounded like they would go with some early drug if they went after this market and would want to partner. One analyst asked about physical function improvement and ScholarRock said that would be shared at some medical conference and downplayed the results saying it was only a 24 week small trial. Now my comment: What company showed physical improvement with their drug in a small trial that only lasted for 16 weeks???

1 · Reply

Weatherby101 Jun. 19 at 9:37 AM

$VERU anyone find anything about yesterday?

1 · Reply

NolAsrtormZ Jun. 19 at 12:42 AM

$VERU Does Mitch steiner know there is only 7 business days left in 2Quarter for his 12 week extension trial🤣🤣🤣🤭🤑

1 · Reply

NolAsrtormZ Jun. 18 at 10:16 PM

$VERU today is probably 2nd round??? Of puts

0 · Reply

NolAsrtormZ Jun. 18 at 10:13 PM

$VERU so i guess 1st trench of put buys was yesterday

0 · Reply

NolAsrtormZ Jun. 18 at 8:47 PM

$VERU what time is fire chat info supposed to release

0 · Reply

AIIAAIIA_88 Jun. 18 at 8:43 PM

$VERU Nice close before holiday. Hopefully we get great data and news next week. JMO

0 · Reply

WallStreetBuyDip Jun. 18 at 8:28 PM

How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.

0 · Reply

Woundntyouliketoknow Jun. 18 at 7:48 PM

$VERU - New article with mention of VERU - Scholar Rock drug preserves muscle in obesity trial https://www.biopharmadive.com/news/scholar-rock-apitegromab-obesity-muscle-results/751016/

1 · Reply

NolAsrtormZ Jun. 18 at 7:02 PM

$VERU wonder what time their fireside chat is today

0 · Reply

adcom707 Jun. 18 at 7:00 PM

$VERU anything came from fireside chat on financing?

0 · Reply

NolAsrtormZ Jun. 18 at 6:12 PM

$VERU if the Data is good should get above $1.00 If Veru wants to run above $1.00 b4 shareholders meeting for 10 days it will be above $1.00 by July 14 to make it🤑🤑🤑

0 · Reply

Market Cap	88.54M
Revenue (ttm)	16.89M
Net Income (ttm)	-37.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.80%
Debt to Equity Ratio	0.00

Volume	612,261
Avg Vol	2,239,870
Day's Range	N/A - N/A
Shares Out	146.58M
Stochastic %K	24%
Beta	-0.80
Analysts	Strong Sell
Price Target	$2.80